Description

EORTC ‘s research into adult Leukemia is mainly concerned with improving the outcomes of patients with leukemias or related hematologic malignancies. We operate through clinical trials, such as large standard-practice changing phase III studies, and run strong translational research programmes analysing epigenetic therapy in acute myeloid leukemia or myelodysplastic syndrome. EORTC works in collaboration with other national and international study groups, particularly the GIMEMA. We are also developing robust survivorship studies, taking advantage of the large number of patients already included in phase III research.

Main Achievements

Demonstrated the superiority of allogeneic vs autologous stem cell transplantation vs intensive consolidation in Acute Myeloid Leukemia (AML) younger patients.

Showed high-dose cytarabine increased remission and survival rates as compared to standard-dose cytarabine, especially in AML patients younger than 46 years old.

Found that first-line monotherapy with low-dose Gemtuzumab Ozogamicin, as compared with Best Supportive Care, significantly improved OS in older AML patients who were ineligible for intensive chemotherapy.

Demonstrated decitabine administered in 6-week cycles is active in older patients with higher-risk MDS, resulting in improvements of OS and AMLFS (nonsignificant), of PFS and AML transformation (significant), and of QOL.

Related Projects

  • RP-1479 (SPARTA): The Survivorship Project to understand and to improve long-Term outcomes for Acute myeloid leukemia patients.
    (Project leaders: F. Efficace / F. Baron) The research project is ongoing.

IMI2 HARMONY – Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY. This project will gather, integrate and analyse anonymous patient data from a number of sources. The project is part of IMI’s Big Data for Better Outcomes programme, which aims to facilitate the use of diverse data sources to deliver results that reflect health outcomes of treatments  that are meaningful for patients, clinicians, regulators, researchers, healthcare decision-makers, and others. (No website available yet)

Research Group

Group documents
  • Chair

    Michael Lübbert

    Universitaetsklinikum Freiburg

    Freiburg, Germany

  • Secretary

    Heiko Becker

    Universitaetsklinikum Freiburg

    Freiburg, Germany

  • Treasurer

    Laimonas Griskevicius

    Vilnius University Hospital Santariskiu Santaros Clinics Klinikos

    Vilnius, Lithuania